8-K: Kiora Pharmaceuticals Receives Regulatory Approval for Phase 2 Retinitis Pigmentosa Trial

Kiora Pharmaceuticals has received regulatory approval to begin a Phase 2 clinical trial for KIO-301, a potential treatment for retinitis pigmentosa.

Summary

• Kiora Pharmaceuticals has announced the regulatory approval to initiate the ABACUS-2 Phase 2 clinical trial for KIO-301, a treatment for retinitis pigmentosa.
• The ABACUS-2 trial will enroll 36 patients across multiple centers in Australia, focusing on individuals with ultra-low vision or no light perception, regardless of the underlying genetic mutation.
• The study will be a double-masked, randomized, controlled trial with multiple doses of KIO-301, with patients randomized 2:1 to receive either KIO-301 or a control treatment.
• Patients will receive either a high dose (100 micrograms) or low dose (50 micrograms) of KIO-301, administered intravitreally to both eyes, with three consecutive doses given six weeks apart, followed by a three-month follow-up.
• The primary endpoints of the trial are safety and tolerability, while key efficacy assessments include functional vision, visual acuity, visual fields, and quality of life.
• KIO-301 is a small molecule photoswitch that aims to restore vision by targeting retinal ganglion cells, and it has the potential to work across various gene mutations associated with inherited retinal diseases.
• The company is also developing KIO-104 for retinal inflammation, with a Phase 2 trial (KLARITY) planned for 2025.
• Kiora has a partnership with Tha Open Innovation, which is funding the development of KIO-301 through Phase 3 trials, with Kiora receiving tiered royalties up to the low 20%.

Sentiment

Score: 8

Explanation: The document is very positive, highlighting regulatory approval, a strong partnership, and promising early clinical data. The company has a clear path forward and is well-funded, which is encouraging for investors.

Positives

• Regulatory approval for the Phase 2 trial of KIO-301 is a significant step forward.
• KIO-301 has the potential to address a large unmet need in retinitis pigmentosa, a disease with no approved therapies.
• The partnership with Tha Open Innovation provides substantial funding and resources for KIO-301's development.
• KIO-301's unique mechanism of action could work across multiple gene mutations, making it a broad-spectrum treatment.
• The company has a strong cash position, expected to fund operations into 2027.
• The Phase 1b study showed promising results with KIO-301 being safe and well-tolerated.
• KIO-104 has shown positive results in preclinical studies and Phase 1/2a trials, with no serious adverse events and good tolerability.

Negatives

• The ABACUS-2 trial is still in the early stages, and success is not guaranteed.
• The company is reliant on external funding and partnerships for the development of its products.
• The company is still in the clinical stage and has no products on the market.
• The company is subject to risks and uncertainties associated with clinical trials and regulatory approvals.

Risks

• Clinical trials may not be successful, and regulatory approvals may not be granted.
• The company may not be able to secure additional funding or partnerships.
• The company may face competition from other companies developing treatments for retinal diseases.
• The company's products may not be commercially successful.
• There are risks associated with the development of novel therapies, including unexpected side effects or lack of efficacy.

Future Outlook

Kiora plans to advance both KIO-301 and KIO-104 through clinical trials, with the goal of bringing new treatments to market for retinal diseases. The company expects to complete the run-in study to validate novel functional vision endpoints in Q1 2025, complete enrollment of ABACUS-2 in 2H 2025, and initiate the KLARITY Phase 2 clinical trial for KIO-104 in 1H 2025.

Management Comments

• Eric Daniels, M.D., Chief Development Officer at Kiora, stated that the ABACUS-2 study represents a significant step toward addressing the challenge of retinitis pigmentosa, for which there are no approved therapies.
• Dr. Cline Olmiere, Head of Tha Open Innovation, noted that tremendous progress has been made on advancing KIO-301 toward ABACUS-2 and that KIO-301 appears to have potential for meaningful vision restoration.

Industry Context

This announcement is significant in the context of the broader industry trend of developing novel therapies for inherited retinal diseases. The focus on functional vision endpoints aligns with regulatory expectations and the need for treatments that improve patients' daily lives. The partnership with Tha Open Innovation highlights the importance of collaboration in bringing innovative treatments to market.

Comparison to Industry Standards

• The development of KIO-301 for retinitis pigmentosa is comparable to other gene-agnostic approaches in the field, such as those being pursued by companies like ProQR Therapeutics and Editas Medicine, though these companies are using different mechanisms of action.
• The focus on functional vision endpoints is consistent with the approach taken by companies like Spark Therapeutics, which developed Luxturna, the first gene therapy for an inherited retinal disease, which also focused on functional vision improvements.
• The partnership with Tha Open Innovation is similar to other collaborations in the biotech industry, where smaller companies partner with larger pharmaceutical companies to fund and commercialize their products, such as the partnership between BioMarin and Sarepta Therapeutics.
• The Phase 1b results of KIO-301 are comparable to other early-stage clinical trials for retinal disease treatments, with a focus on safety and tolerability, and early indications of efficacy.
• The development of KIO-104 as a steroid-sparing anti-inflammatory is similar to other approaches in the field, such as those being pursued by companies like Aldeyra Therapeutics, which are developing novel anti-inflammatory drugs for ocular diseases.

Stakeholder Impact

• Shareholders: The positive news of regulatory approval and clinical trial progress is likely to be well-received by shareholders.
• Patients: The development of KIO-301 offers hope for patients with retinitis pigmentosa, a disease with no approved therapies.
• Employees: The company's progress and financial stability are positive for employees.
• Partners: The partnership with Tha Open Innovation is beneficial for both companies.

Next Steps

• Initiate the ABACUS-2 Phase 2 clinical trial in the second half of 2024.
• Complete the run-in study to validate novel functional vision endpoints in Q1 2025.
• Complete enrollment of the ABACUS-2 trial in the second half of 2025.
• Round out the non-clinical package for KIO-104 in Q4 2024.
• Initiate the KLARITY Phase 2 clinical trial for KIO-104 in the first half of 2025.

Key Dates

Keywords

KIO-301, retinitis pigmentosa, KIO-104, clinical trial, retinal disease, vision restoration, molecular photoswitch, ABACUS-2, Tha Open Innovation, retinal inflammation, DHODH inhibitor